(Press-News.org) Engineering chimeric antigen receptor (CAR) T cells to lower their affinity for the protein epithelial growth factor receptor (EGFR) made the cells preferentially recognize and eliminate tumor cells that have high amounts of EGFR while sparing normal cells that have lower amounts of the protein, according to a preclinical study.
CAR T cells that are currently being tested to treat B-cell malignancies target a specific protein present on leukemia and lymphoma, but these immune cells cannot distinguish cancer cells from normal cells, explained Cooper. Even though such CAR T cells attack cancer cells and normal B cells alike, the side effects are manageable, which may not be the case with solid tumors. "Many proteins that are present on solid tumors may also be present on normal cells that are vital to the body. So, while recipients of CAR T cells can tolerate the loss of normal B cells, they cannot endure damage to vital structures if the engineered T cells inappropriately damage essential tissues. Because of this, CAR T-cell-based immunotherapy may not yet be entirely safe for patients with solid tumors," added Cooper.
To make CAR T-cell therapy applicable to solid tumors, Cooper and his colleagues developed CAR molecules with reduced affinity for a target on solid tumors. The target they chose in this study was wild-type EGFR, a protein that is present at high levels in certain brain cancers, but is also found at low levels on some normal cells. These experiments were performed by Hillary Caruso, PhD, while a graduate student with Cooper.
The researchers used two monoclonal antibodies, cetuximab, which has higher affinity for EGFR, and nimotuzumab, which has lower affinity for EGFR, and from these, they engineered high-affinity cetux-CAR T cells and low-affinity nimo-CAR T cells.
The researchers tested the different CAR T cells on cancer cells with high levels of EGFR and normal cells with low levels of EGFR and found that while the cetux-CAR T cells killed both cancer and normal cells, the nimo-CAR T cells were selectively activated only in response to cancer cells, but not normal cells.
The researchers then tested the CAR T cells in mice bearing human brain cancer cells expressing high levels of EGFR and found that both cetux- and nimo-CAR T cells were equally effective in inhibiting tumor growth. However, the cetux-CAR T cells caused significant toxicity to the mice, leading to death in some, whereas the infused nimo-CAR T cells were safe. The researchers further tested the new CAR T cells in mice bearing cells that had low levels of EGFR (to mimic normal human cells), and found that unlike cetux-CAR T cells, the nimo-CAR T cells did not impact the growth of these cells.
In an interview, Cooper said, "The goal of the study was to make CAR-expressing T cells differentiate friend from foe. We wanted to provide CAR T cells an improved opportunity of targeting a protein that is overexpressed on a cancer cell and spare normal cells that may also have the same protein, but at lower levels.
"We think this provides an advance in the field of CAR T-cell therapy because until now the focus in terms of T-cell activation was on the intracellular portion of the CAR design, which led to the development of second- and third-generation CARs with different abilities to signal T cells. Our study has shown that another possibility is to tweak the extracellular portion of the CAR that docks with the tumor by adjusting its affinity for the target protein," said Cooper. This technology can be used to develop CAR T cells that can be fine-tuned to target other overexpressed cancer proteins besides EGFR, Cooper explained. "An important derivative of this study is that scientists can now tweak, or modulate, the affinity of a CAR T cell to meet the needs of a given tumor."
INFORMATION:
Journal in Which the Study was Published: Cancer Research, a journal of the American Association for Cancer Research
Author: Laurence Cooper, MD, PhD, CEO of ZIOPHARM Oncology in Boston, and formerly, professor of pediatrics at The University of Texas MD Anderson Cancer Center, while conducting this study.
Funding & Disclosures: This study was funded by multiple groups including the National Institutes of Health and private foundations.
In January 2015, the technology was licensed for commercial application to ZIOPHARM Oncology and Intrexon Corporation in exchange for equity interests in each of these companies and, as a result, Cooper and some of the authors of this study have a financial interest in ZIOPHARM Oncology Inc. and Intrexon Corporation.
For further reading:
CAR T-cell Therapy: Engineering Patients' Immune Cells to Treat Their Cancers
Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 101 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 25 conferences and educational workshops, the largest of which is the AACR Annual Meeting with almost 19,300 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.
To interview Laurence Cooper, contact Julia Gunther at julia.gunther@aacr.org or 215-446-6896.
In recent years, an effort has been underway to redefine malnutrition in pediatric patients to include both the acute clinical population and the more traditional ambulatory populations. Identifying and treating malnutrition in pediatric patients is important from an acute standpoint and to ensure that children have enough nutrition to reach optimal final height and development.
Pediatric malnutrition in the clinical setting was recently defined by the Academy of Nutrition and Dietetics and A.S.P.E.N. as "an imbalance between nutrient requirements and intake that results ...
ANN ARBOR--Daily marijuana use among the nation's college students is on the rise, surpassing daily cigarette smoking for the first time in 2014.
A series of national surveys of U.S. college students, as part of the University of Michigan's Monitoring the Future study, shows that marijuana use has been growing slowly on the nation's campuses since 2006.
Daily or near-daily marijuana use was reported by 5.9 percent of college students in 2014--the highest rate since 1980, the first year that complete college data were available in the study. This rate of use is up ...
The fossil of a previously unknown species of 'sea scorpion', measuring over 1.5 meters long, has been discovered in Iowa, USA, and described in the open access journal BMC Evolutionary Biology.
Dating back 460 million years, it is the oldest known species of eurypterid (sea scorpion) - extinct monster-like predators that swam the seas in ancient times and are related to modern arachnids.
The authors named the new species Pentecopterus decorahensis after the 'penteconter' - an ancient Greek warship that the species resembles in outline and parallels in its predatory ...
Many of the most memorable stories in the history of science revolve around the conscious realization of an idea - the "Eureka!" moment. But what triggers these moments? Is there always some serendipitous event preceding a sudden epiphany, such as when Isaac Newton famously figured out gravity when he saw a falling apple?
Writing in September's Physics World, Vitor Cardoso talks about how these questions led him on a quest of discovery through the web-based project The Birth of an Idea, which he co-founded with artist Ana Souse Carvalho.
"Ana and I had been talking ...
Women living in poor areas in the UK are almost twice as likely to develop clinical anxiety as women in richer areas. However, whether men lived in poorer or richer areas made no difference to their levels of generalised anxiety disorder (GAD). These are amongst the main findings of a major survey on how socio-economic factors affect mental health in the UK.
Generalised anxiety disorder is one of the most common mental health conditions in modern society, but little objective work has taken place to show the factors in society which can lead to the development of anxiety. ...
How do you convince someone with schizophrenia or other psychotic disorders that they are ill if they don't want to believe it? If you don't recognize that you are ill, you may resist treatment, but is there something which causes this lack of awareness? Awareness of illness, also known as 'insight', is a serious problem in the treatment of psychotic patients. Now work being presented at the ECNP Congress in Amsterdam investigates whether concentrations of a marker of brain cell dysfunction are associated with impaired insight.
Past studies have indicated that an area ...
Men with relatively unaggressive prostate tumors and whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to results of a study by researchers at the Brady Urological Institute at Johns Hopkins, who analyzed survival statistics up to 15 years.
Specifically, the researchers report, just two of 1,298 men enrolled over the past 20 years in a so-called active surveillance program at Johns Hopkins died of prostate cancer, and three developed metastatic disease.
"Our study should reassure ...
Lincoln, Neb., Aug. 31, 2015 -- Using an enormous X-ray laser -- one of only two such machines on Earth -- University of Nebraska-Lincoln physicist Matthias Fuchs and scientists from around the world beat formidable odds to observe one of the most fundamental interactions between X-rays and matter.
The findings can aid future studies and may lead to novel new ways to diagnose matter in the future.
Fuchs and his colleagues induced two X-ray photons to simultaneously collide with a single atom, which converts them into a single higher-energetic X-ray photon. It's a phenomenon ...
New York, NY--August 31, 2015--With the rise of CO2 in Earth's atmosphere, understanding the climate of tropical forests--the Amazon in particular--has become a critical research area. A recent NASA study showed that these regions are the biggest terrestrial carbon dioxide sinks on our planet, absorbing 1.4 billion metric tons of CO2 out of a total global terrestrial absorption of 2.5 billion. To simulate the tropical climate to learn more about its processes, climate scientists have typically been relying on general circulation models (GCMs) to simulate the tropical climate. ...
Longer, less frequent climate fluctuations may be contributing to abrupt and unexplained ecosystem shifts in the North Pacific, according to a study by the University of Exeter.
Researchers have long been puzzled by two rapid and widespread changes in the abundance and distribution of North Pacific plankton and fish species that impacted the region's economically important salmon fisheries. In 1977, and again in 1989, the number of salmon in some areas plummeted, while it increased in other areas. These events have been dubbed regime shifts by researchers.
Now, in ...
